Clinical and Functional Effectiveness of Botulinum Toxin in Temporomandibular Disorders: A Systematic Review of Randomized Controlled Trials
Current evidence does not support the routine use of BoNT-A as a first-line treatment for TMDs overall, and BoNT-A may represent an adjunctive or second-line option for selected patients with myogenous TMD, localized myofascial pain, or marked masticatory muscle hyperactivity who do not adequately respond to convention...